Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12361962 | 0.92 | TRPM8 (0.34) | NPC1RAB9A | |
| SCHEMBL1644355 | 0.87 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL12380779 | 0.87 | NPC1 (0.30) | NPC1RAB9A | |
| SCHEMBL12361827 | 0.87 | NPC1 (0.31) | NPC1RAB9AATM | |
| SCHEMBL12774655 | 0.86 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL12361825 | 0.86 | NPC1 (0.33) | NPC1RAB9AKDM4EMAPTMAPK1 | |
| SCHEMBL12361872 | 0.85 | NPC1 (0.32) | NPC1RAB9AMAPTCASP3ATM | |
| SCHEMBL1645082 | 0.83 | RAB9A (0.35) | NPC1RAB9AKDM4EMAPT | |
| SCHEMBL12380141 | 0.82 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL12361961 | 0.82 | NPC1 (0.33) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | NPC1 3550/4885RAB9A 3650/4885KDM4E 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.